<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01581853</url>
  </required_header>
  <id_info>
    <org_study_id>KMON</org_study_id>
    <secondary_id>2011-005981-39</secondary_id>
    <nct_id>NCT01581853</nct_id>
  </id_info>
  <brief_title>Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily</brief_title>
  <official_title>Pilot Simplification Study to Lopinavir/Ritonavir 800/200 mg Monotherapy Regimen Once Daily</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel Podzamczer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lopinavir/ritonavir monotherapy is currently a well known and widely used strategy, while
      Lopinavir/ritonavir 800/200 mg once a day in a triple-therapy was approved a few years ago.
      The purpose of this study is to evaluate efficacy and safety of Lopinavir/ritonavir 800/200
      mg monotherapy once a day.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>plasma viral load &lt;40 copies/mL</measure>
    <time_frame>Week 48</time_frame>
    <description>HIV Plasma Viral Load &lt;40 copies/ml at week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stability in the plasma levels of Lopinavir/ritonavir during all study visits</measure>
    <time_frame>Weeks 4, 8, 12, 16, 24, 36 and 48</time_frame>
    <description>Determination of plasma concentrations of the study drug at weeks 4, 8, 12, 16, 24, 36 and 48</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability</measure>
    <time_frame>Weeks 4, 8, 12, 16, 24, 36 and 48</time_frame>
    <description>Possible Adverse Events will be collected in all study visits and laboratory tests will also be performed in all study visits (weeks 4, 8, 12, 16, 24, 36 and 48)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence</measure>
    <time_frame>Weeks 4, 8, 12, 16, 24, 36 and 48</time_frame>
    <description>Medication adherence will be evaluated in all the study visits after making a reconciliation of the medication dispensed and returned by the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>Weeks 4, 8, 12, 16, 24, 36 and 48</time_frame>
    <description>Patients' satisfaction with the new regimen will be evaluated using a questionnaire (SMAQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>- Efficacy in CSF</measure>
    <time_frame>At least 4 weeks on study treatment</time_frame>
    <description>- In a subsample of patients (10) HIV-1 RNA in CSF will be assessed (added as per amendment)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Lopinavir/ritonavir 800 mg / 200mg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Kaletra 200/50 mg comprimidos recubiertos con película Lopinavir/ritonavir 800 mg / 200mg will be changed from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ritonavir 800 mg / 200mg</intervention_name>
    <description>Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months</description>
    <arm_group_label>Lopinavir/ritonavir 800 mg / 200mg</arm_group_label>
    <other_name>Kaletra 200/50 mg comprimidos recubiertos con película</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18, HIV positive

          -  Patients receiving a monotherapy regimen (Lopinavir/ritonavir twice daily)during the
             last 6 months

          -  Undetectable viral load (&lt;40 copies/ml) during the last 6 months

          -  Patients that accept participation in the study and sign the Informed Consent Form

          -  Childbearing females with negative pregnancy tests and using appropriate contraceptive
             measures

        Exclusion Criteria:

          -  Opportunistic disease, cancer or any other active disease with specific treatment

          -  Active addiction to illegal drugs or active use of psychotropic drugs

          -  Mental retardation diagnosis, or mental dementia or severe psychiatric disorder
             (excluding major depression disorder solved &gt; 3 months)

          -  Females who are breastfeeding or pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Podzamczer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hernando Knobel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Bercelona</city>
        <state>Barcelona</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitary de Bellvitge</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2012</study_first_submitted>
  <study_first_submitted_qc>April 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2012</study_first_posted>
  <last_update_submitted>October 5, 2016</last_update_submitted>
  <last_update_submitted_qc>October 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Daniel Podzamczer</investigator_full_name>
    <investigator_title>MD. HIV/AIDS Program Director. HIV Unit. Infectious Disease Service</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>AIDS</keyword>
  <keyword>MONOTHERAPY</keyword>
  <keyword>PILOT</keyword>
  <keyword>LOPINAVIR/RITONAVIR</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

